Novocure LTD

Novocure announced record net revenues and active patients for Q2 2026, driven by global growth and the launch of Optune Pax, leading to an upward revision of its full-year financial outlook.

Novocure announced its Optune Pax device has received CE Mark for locally advanced pancreatic cancer, showing improved overall survival and delayed pain progression in a Phase 3 trial.

Novocure's Phase 3 TRIDENT trial for newly diagnosed glioblastoma did not show a statistically significant improvement in overall survival for earlier initiation of Tumor Treating Fields therapy.

NovoCure shareholders elected eleven directors and approved the Amended and Restated 2024 Omnibus Incentive Plan at the 2026 Annual Meeting.

Novocure announced first quarter 2026 financial results, showcasing a 12% year-over-year revenue increase driven by global Optune Gio growth and the promising launch of Optune Pax for pancreatic cancer.

NovoCure Limited filed an amendment to its 8-K detailing the compensation and employment agreement for CEO Frank Leonard.

NovoCure Limited reported a 16% increase in net revenues for Q2 2026, driven by patient growth and new product contributions, while managing operating expenses and investing in future development.

NovoCure Limited announced its first-quarter 2026 financial results, reporting a 12% increase in net revenues to $174.1 million, driven by international market growth, while net loss widened due to increased operating expenses.

NovoCure Limited reported an 8% increase in net revenues for Q3 2025, reaching $167.2 million, but saw net losses widen to $37.3 million and Adjusted EBITDA turn negative.

NovoCure Limited announced its second quarter 2025 financial results, showing a 6% increase in net revenues to $158.8 million, driven by patient growth and international market expansion, despite a widening net loss and reduced gross margin.

NovoCure Limited reports a 12% increase in net revenues for Q1 2025, driven by active patient growth and reimbursement improvements.

NovoCure's Q3 2024 results show a 22% increase in net revenue year-over-year, driven by growth in the US and a successful launch in France.

NovoCure Limited reports 8% revenue growth to $655.4 million in 2025, driven by Optune Gio adoption and new product launches, despite continued operating losses and increased R&D spending.

NovoCure's 10-K filing highlights a year of revenue growth, clinical trial progress, and strategic pipeline expansion, balanced against ongoing operating losses and market competition.

NovoCure's 2023 annual report highlights progress in commercializing its Tumor Treating Fields (TTFields) therapy and advancing clinical trials, with a focus on potential approval for non-small cell lung cancer (NSCLC).

NovoCure Ltd. reports that Chief Human Resources Officer Michal Nath Puri acquired ordinary shares through the company's Employee Stock Purchase Plan.

NovoCure Ltd. reports that CEO Frank X. Leonard acquired 1,905 ordinary shares through the company's Employee Stock Purchase Plan.

NovoCure CEO Frank Leonard sold 34,273 shares to satisfy tax withholding obligations related to the vesting of restricted stock units.

Director Gabriel Leung was granted 11,610 restricted stock units and 16,999 stock options by NovoCure Ltd.

Director Kristin Stafford was granted 11,610 restricted stock units and 16,999 stock options as part of annual compensation.

Director Allyson J. Ocean was granted 11,610 restricted stock units and 16,999 stock options by NovoCure Ltd.

NovoCure Limited has filed its definitive proxy statement for the 2026 Annual General Meeting of Shareholders to be held on June 3, 2026.

NovoCure Limited has scheduled its annual shareholder meetings for June 5, 2024, and June 4, 2025, with proxy materials available online and via mail.

NovoCure has announced its Annual General Meeting of Shareholders to be held on June 4, 2025, featuring proposals including director elections, auditor ratification, executive compensation approval, and the approval of the 2025 Employee Share Purchase Plan.

NovoCure Limited has scheduled its 2024 Annual Meeting for June 5, 2024, and is providing proxy materials to shareholders for voting on key proposals.

NovoCure is asking shareholders to approve the 2024 Omnibus Incentive Plan to replace the 2015 plan, aiming to continue attracting and retaining key talent through equity-based awards.

Soleus Capital Master Fund and affiliated entities have reported a 9.1% beneficial ownership stake in Novocure Limited.

Vanguard Portfolio Management has reported a beneficial ownership of 5.57% in Novocure Ltd's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Novocure Ltd, reporting 0% beneficial ownership following an internal corporate realignment.

Soleus Capital Master Fund and related entities have disclosed a 7.6% beneficial ownership stake in NovoCure Limited, totaling 8,530,665 ordinary shares.

Capital World Investors reported a 1.8% beneficial ownership stake in NovoCure Ltd., holding 2 million shares as of September 30, 2025.

Soleus Capital Master Fund and related entities have reported a beneficial ownership of 8.6% in NovoCure Limited, totaling 9,644,872 ordinary shares.